»This relatively small study primarily has the safety, tolerability and effects of Nilotinib tested for Alzheimer’s biomarkers – and successfully, «says Professor Dr. Richard Dodel, Neurologist at the University of Duisburg-Essen. »However, the study had too few patients or was not designed to allow a progressive assessment of dementia. Nevertheless, we hope that the positive trend regarding cognitive tests can be confirmed in large clinical studies in the future. It may be necessary to treat the patient at even earlier stages of the disease in order to see disease-modifying benefits in the long term. «The US study authors are also proposing a larger multicenter study in order to further investigate whether Nilotinib at Alzheimer could actually become a therapy option someday.
–
